Brainsway (NASDAQ:BWAY) Given Hold (C) Rating at Weiss Ratings

Key Points

• Brainsway's stock has been restated with a "hold (C)" rating by Weiss Ratings, while other analysts have issued varying ratings including an upgrade to "buy" by Wall Street Zen.
• The company's shares are trading at approximately $15.28, with a 52-week range between $7.84 and $17.00.
• Brainsway reported earnings of $0.10 per share for the last quarter, exceeding expectations and setting its FY 2025 guidance at 0.08 EPS.

Brainsway (NASDAQ:BWAY - Get Free Report)'s stock had its "hold (c)" rating restated by stock analysts at Weiss Ratings in a report released on Tuesday,Weiss Ratings reports.

Several other equities research analysts have also recently commented on BWAY. Northland Securities boosted their price target on shares of Brainsway from $15.00 to $19.00 and gave the stock an "outperform" rating in a research report on Thursday, August 14th. Wall Street Zen upgraded shares of Brainsway from a "hold" rating to a "buy" rating in a research report on Sunday, August 17th. Finally, HC Wainwright reiterated a "buy" rating and issued a $17.00 price target on shares of Brainsway in a research report on Monday, August 25th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Brainsway currently has a consensus rating of "Moderate Buy" and an average price target of $18.00.

Brainsway Price Performance

Shares of NASDAQ BWAY traded up $0.12 during midday trading on Tuesday, reaching $15.28. 8,566 shares of the company traded hands, compared to its average volume of 55,978. Brainsway has a 52 week low of $7.84 and a 52 week high of $17.00. The stock has a 50-day moving average price of $14.83 and a 200 day moving average price of $12.03. The company has a market cap of $290.32 million, a price-to-earnings ratio of 58.77 and a beta of 1.23.

Brainsway (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.07 by $0.03. Brainsway had a net margin of 11.60% and a return on equity of 8.97%. The business had revenue of $12.63 million for the quarter, compared to analysts' expectations of $12.34 million. Brainsway has set its FY 2025 guidance at EPS. As a group, analysts expect that Brainsway will post 0.08 EPS for the current year.

Hedge Funds Weigh In On Brainsway

A number of institutional investors have recently bought and sold shares of BWAY. Huntleigh Advisors Inc. grew its stake in Brainsway by 5.7% during the 2nd quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company's stock valued at $1,018,000 after acquiring an additional 4,143 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Brainsway during the 2nd quarter valued at about $85,000. NewEdge Advisors LLC grew its stake in Brainsway by 34.5% during the 2nd quarter. NewEdge Advisors LLC now owns 26,665 shares of the company's stock valued at $351,000 after acquiring an additional 6,837 shares in the last quarter. GAMMA Investing LLC grew its stake in Brainsway by 720.7% during the 1st quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock valued at $89,000 after acquiring an additional 8,216 shares in the last quarter. Finally, ARK Investment Management LLC grew its stake in Brainsway by 6.1% during the 2nd quarter. ARK Investment Management LLC now owns 199,826 shares of the company's stock valued at $2,628,000 after acquiring an additional 11,498 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company's stock.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.